Skip to content

The Effects of Short Course Enhanced External Counterpulsation Combined with Loop Diuretics on the Kidney and Cardiovascular System in Patients with Cardiorenal Syndrome

The Effects of Short Course Enhanced External Counterpulsation Combined with Loop Diuretics on the Kidney and Cardiovascular System in Patients with Cardiorenal Syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400087662
Enrollment
Unknown
Registered
2024-08-01
Start date
2023-11-16
Completion date
Unknown
Last updated
2024-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiorenal Syndrome

Interventions

Intervention group:Short Course Enhanced External Counterpulsation Combined with Loop Diuretics
Control group:Conventional therapy

Sponsors

The Third Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) Age = 18 years old; Gender unlimited; 2) Those who meet the diagnostic criteria for cardiorenal syndrome; 3) Determine the diagnosis of acute heart failure based on underlying cardiovascular disease, triggers, clinical manifestations (medical history, symptoms and signs), and various examinations (electrocardiogram, chest X-ray, echocardiography, NT proBNP = 300pg/ml); 4) Acute left heart failure complicated by acute AKI, with an increase of = 26.5µmol/L in blood creatinine within 48 hours, blood creatinine increases by = 1.5 times within 7 days or urine volume125pg/ml); 6) Diagnose chronic renal failure based on a history of basic kidney disease or nocturia, as well as various tests such as hemoglobin, blood calcium, blood phosphorus, iPTH, and renal ultrasound; 7) Voluntarily participate and sign an informed consent form. All answers above are "yes", and this subject can participate in the experiment.

Exclusion criteria

Exclusion criteria: 1) Pregnant and lactating women; 2) Patients who are unwilling or unable to cooperate with the study; 3) Patients with severe liver, brain, kidney, and mental illnesses; Patients with severe arrhythmia; Patients with aortic aneurysm or aortic dissection; Patients with significant hemodynamic disorders caused by heart valve disease and congenital heart disease; Patients with coagulation dysfunction; Malignant tumor patients; Patients with systolic blood pressure = 180 mmHg and/or diastolic blood pressure = 110 mmHg; Cardiogenic shock; Severe breathing difficulties accompanied by significant hypoxemia; Hemodynamic instability; End stage renal disease, anuria, urinary tract stenosis, stones, tumors, etc. which cause urinary disorders. 4) Patients who are considered unsuitable for inclusion due to other serious illnesses. If any of the above answers are "yes", this subject cannot participate in the experiment.

Design outcomes

Primary

MeasureTime frame
Creatinine;The absolute changes of 24-hour intake and output;

Secondary

MeasureTime frame
Estimated glomerular filtration rate (eGFR);Blood urea nitrogen (BUN);Cystatin C;Urinary protein/creatinine ratio;Weight;N-terminal B-type natriuretic peptide precursor;Left ventricular ejection fraction;Maximal oxygen uptake;Endothelin-1;Vascular endothelial growth factor;Interleukin-10;Nitric oxide;

Countries

China

Contacts

Public ContactZhaojun Xiong

The Third Affiliated Hospital of Sun Yat-sen University

zhaojunxiong1228@163.com+86 135 8033 6306

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026